Glycoprotein Ⅱb/Ⅲa inhibitors are used as an adjunct to antiplatelet therapy in percutaneous coronary intervention to reduce postprocedural enzyme elevations. Previous studies have shown a risk for thrombocytopenia that is associated with these agents. We sought to evaluate the incidence and outcomes of glycoprotein Ⅲb/Ⅲa inhibitor-associated thrombocytopenia in an unselected series of patients undergoing percutaneous coronary intervention. We reviewed 984 interventions performed on 908 subjects over a specific time period. Glycoprotein Ⅲb/Ⅳa inhibitors were used in 58.8%of cases. Their use increased from 38 to 82%during the study period(p 0.05). The occurrence of thrombocytopenia was not associated with increased in-hospitalmortality, 1-yearmortality,myocardial infarction or revascularization, but was associated with a hospital stay twice as long as in those patients without thrombocytopenia(5.6±11.3 vs. 2.1±2.2 days, p< 0.001). Of the 5.4%of patients who developed thrombocytopenia, only 2 patients(7.1%) required platelet or blood cell transfusion.
展开▼
